Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors

PURPOSE: To evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of trebananib (AMG 386)—a first-in-class angiopoietin-1/2 antagonist peptide-Fc fusion protein—in Japanese patients, we conducted a phase 1, dose escalation study. METHODS: Eligible patients were men or women, ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Toshihiko, Ohtsu, Atsushi, Fuse, Nozomu, Yoshino, Takayuki, Tahara, Makoto, Shibayama, Kazuhiro, Takubo, Takatoshi, Weinreich, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535401/
https://www.ncbi.nlm.nih.gov/pubmed/23124648
http://dx.doi.org/10.1007/s00280-012-2000-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535401/
https://www.ncbi.nlm.nih.gov/pubmed/23124648
http://dx.doi.org/10.1007/s00280-012-2000-1

Ejemplares similares